ArticleDermatology practical & conceptual2025

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy.

Federico Pirro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.